Top

Published in:

01-01-2010 | Preclinical study

Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients

Authors: Shuzhen Liu, Stephen K. Chia, Erika Mehl, Samuel Leung, Ashish Rajput, Maggie C. U. Cheang, Torsten O. Nielsen

Published in: Breast Cancer Research and Treatment | Issue 1/2010

Abstract

Estrogen receptor status in breast cancer is associated with response to hormonal therapy and clinical outcome. The additional value of progesterone receptor (PR) has remained controversial. We examine the value of PR for prognosis and response to tamoxifen on a population-based series of 4,046 invasive early stage breast cancer patients. Clinical information for age at diagnosis, stage, pathology, treatment and outcome was assembled for the study cohort; the median follow-up was 12.4 years. PR status was determined by immunohistochemistry using a rabbit monoclonal antibody on tissue microarrays built from breast tumor surgical excisions. Survival analyses, Kaplan–Meier functions and Cox proportional hazards regression models were applied to assess the associations between PR and breast cancer specific survival. Progesterone receptor was positive in 51% of all cases and 67% of estrogen receptor positive (ER+) cases. Survival analyses for both the whole cohort and ER+ cases given tamoxifen therapy showed that patients with PR+ tumors had 24% higher relative probability for breast cancer specific survival as compared to PR− patients, adjusted for ER, HER2, age at diagnosis, grade, tumor size, lymph node status and lymphovascular invasion covariates. Higher PR expression showed stronger association with patient survival. Log-likelihood ratio tests of multivariate Cox proportional hazards regression models demonstrated that PR was an independent statistically significant factor for breast cancer specific survival in both the whole cohort and among ER+ cases treated with tamoxifen. PR adds significant prognostic value in breast cancer beyond that obtained with estrogen receptor alone.

Available only for authorised users

Nguyen PL, Taghian AG, Katz MS et al (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26:2373–2378. doi:10.1200/JCO.2007.14.4287 CrossRefPubMed

Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 295:2492–2502. doi:10.1001/jama.295.21.2492 CrossRefPubMed

Nadji M, Gomez-Fernandez C, Ganjei-Azar P et al (2005) Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol 123:21–27. doi:10.1309/4WV79N2GHJ3X1841 CrossRefPubMed

Ibrahim M, Dodson A, Barnett S et al (2008) Potential for false-positive staining with a rabbit monoclonal antibody to progesterone receptor (SP2): findings of the UK National external quality assessment scheme for immunocytochemistry and FISH highlight the need for correct validation of antibodies on introduction to the laboratory. Am J Clin Pathol 129:398–409. doi:10.1309/2YXRLEQVPPNRWHGA CrossRefPubMed

ASCO Tumor Marker Expert Panel (1996) Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 14:2843–2877

Anderson WF, Chatterjee N, Ershler WB et al (2002) Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res Treat 76:27–36. doi:10.1023/A:1020299707510 CrossRefPubMed

Hede K (2008) Breast cancer testing scandal shines spotlight on black box of clinical laboratory testing. J Natl Cancer Inst 100:836–837. doi:10.1093/jnci/djn200 CrossRefPubMed

Cui X, Zhang P, Deng W et al (2003) Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 17:575–588. doi:10.1210/me.2002-0318 (erratum appears in Mol Endocrinol. 2003 Sep;17(9):1892)CrossRefPubMed

Cui X, Schiff R, Arpino G et al (2005) Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 23:7721–7735. doi:10.1200/JCO.2005.09.004 CrossRefPubMed

10.

Stendahl M, Ryden L, Nordenskjold B et al (2006) High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res 12:4614–4618. doi:10.1158/1078-0432.CCR-06-0248 CrossRefPubMed

11.

Ma Y, Qian Y, Wei L et al (2007) Population-based molecular prognosis of breast cancer by transcriptional profiling. Clin Cancer Res 13:2014–2022. doi:10.1158/1078-0432.CCR-06-2222 CrossRefPubMed

12.

Olivotto IA, Truong PT, Speers CH et al (2004) Time to stop progesterone receptor testing in breast cancer management. J Clin Oncol 22:1769–1770. doi:10.1200/JCO.2004.99.251 CrossRefPubMed

13.

Banerjee M, George J, Song EY et al (2004) Tree-based model for breast cancer prognostication. J Clin Oncol 22:2567–2575. doi:10.1200/JCO.2004.11.141 CrossRefPubMed

14.

MacGrogan G, de Mascarel I, Sierankowski G et al (2005) Time for reappraisal of progesterone-receptor testing in breast cancer management. J Clin Oncol 23:2870–2871. doi:10.1200/JCO.2005.05.241 (author reply 2871)CrossRefPubMed

15.

Olivotto A, Coldman AJ, Hislop TG et al (1997) Compliance with practice guidelines for node-negative breast cancer. J Clin Oncol 15:216–222PubMed

16.

Cheang MC, Treaba DO, Speers CH et al (2006) Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol 24:5637–5644. doi:10.1200/JCO.2005.05.4155 CrossRefPubMed

17.

Cheang MC, Voduc D, Bajdik C et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368–1376. doi:10.1158/1078-0432.CCR-07-1658 CrossRefPubMed

18.

Chia S, Norris B, Speers C et al (2008) Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 26:5697–5704. doi:10.1200/JCO.2007.15.8659 CrossRefPubMed

19.

Ng TL, Gown AM, Barry TS et al (2005) Nuclear beta-catenin in mesenchymal tumors. Mod Pathol 18:68–74. doi:10.1038/modpathol.3800272 CrossRefPubMed

20.

Dowsett M, Allred C, Knox J et al (2008) Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26:1059–1065. doi:10.1200/JCO.2007.12.9437 CrossRefPubMed

21.

Castagnetta LA, Traina A, Liquori M et al (1999) Quantitative image analysis of estrogen and progesterone receptors as a prognostic tool for selecting breast cancer patients for therapy. Anal Quant Cytol Histol 21:59–62PubMed

22.

MacGrogan G, Soubeyran I, de Mascarel I (1996) Immunohistochemical detection of progesterone receptors in breast invasive ductal carcinomas: a correlative study of 942 cases. Appl Immunohistochem 4:9

23.

Viale G, Regan MM, Maiorano E et al (2007) Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1–98. J Clin Oncol 25:3846–3852. doi:10.1200/JCO.2007.11.9453 CrossRefPubMed

24.

Singh M, Zaino RJ, Filiaci VJ et al (2007) Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol 106:325–333. doi:10.1016/j.ygyno.2007.03.042 CrossRefPubMed

25.

Mohsin SK, Weiss H, Havighurst T et al (2004) Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol 17:1545–1554. doi:10.1038/modpathol.3800229 [erratum appears in Mod Pathol. 2005 Mar;18(3):461 Note: Qian, Zho (corrected to Qian, Zhang)]CrossRefPubMed

26.

Linke SP, Bremer TM, Herold CD et al (2006) A multimarker model to predict outcome in tamoxifen-treated breast cancer patients. Clin Cancer Res 12:1175–1183. doi:10.1158/1078-0432.CCR-05-1562 CrossRefPubMed

27.

Tovey S, Dunne B, Witton CJ et al (2005) Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin Cancer Res 11:4835–4842. doi:10.1158/1078-0432.CCR-05-0196 CrossRefPubMed

28.

Loi S, Haibe-Kains B, Desmedt C et al (2008) Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 9:239. doi:10.1186/1471-2164-9-239 CrossRefPubMed

29.

Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451–1467. doi:10.1016/S0140-6736(97)11423-4 CrossRef

30.

Ravdin PM, Green S, Dorr TM et al (1992) Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest oncology group study. J Clin Oncol 10:1284–1291PubMed

31.

Ciocca DR, Elledge R (2000) Molecular markers for predicting response to tamoxifen in breast cancer patients. Endocr 13:1–10. doi:10.1385/ENDO:13:1:1 CrossRef

32.

Creighton CJ, Kent Osborne C, van de Vijver MJ et al. (2008) Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat. doi:10.1007/s10549-008-0017-2 PubMed

33.

Osborne CK, Yochmowitz MG, Knight WAIII et al (1980) The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46:2884–2888. doi:10.1002/1097-0142(19801215)46:12+<2884::AID-CNCR2820461429>3.0.CO;2-U CrossRefPubMed

34.

Olivotto IA, Bajdik CD, Ravdin PM et al (2005) Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23:2716–2725. doi:10.1200/JCO.2005.06.178 CrossRefPubMed

Title: Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients
Authors: Shuzhen Liu
Stephen K. Chia
Erika Mehl
Samuel Leung
Ashish Rajput
Maggie C. U. Cheang
Torsten O. Nielsen
Publication date: 01-01-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0318-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms

The impact of sociodemographic, treatment, and work support on missed work after breast cancer diagnosis

Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group

Bisphosphonate-related osteonecrosis of the jaw in randomized clinical trials

Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers

Prognosis of BRCA-associated breast cancer: a summary of evidence

Keynote webinar | Spotlight on antibody–drug conjugates in cancer